Eli Lilly has entered into an agreement with the European Commission to supply up to 220,000 doses of bamlanivimab and etezavimab for the treatment of coronavirus in patients 12 years and older with an increased risk of disease progression and who do not require supplemental oxygen. The amount of medicine to be procured is subject to change depending on the needs determined by EEC and EEA countries.